Today: 7 February 2026
Subscribe
Browse Category

NYSE:ABBV News 26 January 2026 - 6 February 2026

AbbVie stock rises as investors re-rank Rinvoq and Skyrizi after earnings jolt

AbbVie stock rises as investors re-rank Rinvoq and Skyrizi after earnings jolt

AbbVie shares climbed 2% to $223.45 in midday trading Friday after a volatile week. The move followed a quarterly report showing fourth-quarter net revenues up 10% to $16.62 billion and adjusted profit of $2.71 per share. Humira sales dropped 25.9% as biosimilar competition increased, while Skyrizi and Rinvoq posted gains. The company also announced new regulatory approvals and licensing deals.
6 February 2026
·····
AbbVie stock ticks higher after hours as traders digest 2026 outlook after Rinvoq miss

AbbVie stock ticks higher after hours as traders digest 2026 outlook after Rinvoq miss

AbbVie shares rose 0.7% to $219.02 in after-hours trading Thursday, rebounding after a nearly 6% drop following its earnings report. Skyrizi beat sales estimates with $5.01 billion, while Rinvoq missed at $2.37 billion. The company raised its 2026 forecast for the pair to $31.6 billion. Investors remain focused on whether new drugs can offset Humira’s ongoing decline.
6 February 2026
·····
AbbVie stock slides after earnings: Rinvoq miss dents ABBV despite upbeat 2026 view

AbbVie stock slides after earnings: Rinvoq miss dents ABBV despite upbeat 2026 view

AbbVie shares fell 3.9% in after-hours trading Wednesday after quarterly results showed Rinvoq sales missed expectations at $2.37 billion. Skyrizi sales beat forecasts at $5.01 billion, while Humira revenue dropped 25.9% to $1.25 billion. The company projected 2026 adjusted earnings above estimates, but investors focused on challenges replacing Humira as biosimilar competition grows.
5 February 2026
·····
AbbVie stock drops after Rinvoq sales miss, even as 2026 profit forecast tops estimates

AbbVie stock drops after Rinvoq sales miss, even as 2026 profit forecast tops estimates

AbbVie shares fell 2.5% to $219.98 Wednesday after Rinvoq sales missed forecasts, despite the company raising its 2026 profit outlook. Q4 adjusted earnings reached $2.71 per share on $16.618 billion revenue; Skyrizi sales rose 32.5%, while Humira dropped 25.9%. AbbVie announced a three-year Medicaid pact with the Trump administration and pledged $100 billion in U.S. investments.
4 February 2026
·····
AbbVie stock ticks up ahead of earnings after Rinvoq vitiligo filing—what investors watch next

AbbVie stock ticks up ahead of earnings after Rinvoq vitiligo filing—what investors watch next

AbbVie shares rose 0.8% to $227.55 Tuesday afternoon ahead of its quarterly earnings report due Wednesday morning. The company filed with U.S. and European regulators to expand Rinvoq’s use to non-segmental vitiligo, based on Phase 3 data. Investors are watching whether new immunology drugs can offset Humira’s sales decline.
3 February 2026
····
AbbVie stock gains ahead of earnings; ABBV investors brace for guidance and a $1.3 billion expense

AbbVie stock gains ahead of earnings; ABBV investors brace for guidance and a $1.3 billion expense

New York, February 2, 2026, 16:10 (EST) — After-hours trading AbbVie shares climbed $2.69, or 1.2%, on Monday, settling at $225.70 after hitting a session high of $229.80. AbbVie is set to release full-year and fourth-quarter earnings on Wednesday. Investors will be watching to see if its newer products can step up as Humira’s sales decline amid growing competition from generics. This is crucial now since the stock can’t afford to wander. Investors demand the numbers first, then the outlook — and both need to meet the high expectations already established in large-cap healthcare. Monday’s market moved more quietly, with
2 February 2026
·····
AbbVie stock rises into weekend as Feb. 4 earnings loom — what traders watch next

AbbVie stock rises into weekend as Feb. 4 earnings loom — what traders watch next

AbbVie shares closed Friday at $223.01, up 1.2%, outpacing big pharma peers as trading volume topped its 50-day average. The company reports earnings Wednesday, with analysts watching Skyrizi, Rinvoq, and the aesthetics segment. AbbVie’s full-year adjusted earnings guidance stands at $9.90 to $9.94. Investors remain cautious amid macroeconomic uncertainty and upcoming U.S. jobs data.
1 February 2026
····
Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer shares fell 1.8% to $26.02 after U.S. Medicare included Xeljanz in its upcoming drug price negotiations, set to begin in 2026 with prices effective in 2028. The Centers for Medicare & Medicaid Services named 15 drugs for talks, and companies must decide by February 28 whether to participate. Investors are awaiting Pfizer’s February 3 earnings for updates on pricing risks.
28 January 2026
·······
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly shares closed down 2.3% at $1,039.51 Tuesday, then rose 0.3% after hours. U.S. Medicare officials named Lilly’s Trulicity among 15 drugs for 2028 price negotiations. The stock has dropped three straight sessions and now trades about 8% below its Jan. 8 peak. Investors await Lilly’s Feb. 4 earnings for updates on diabetes and obesity drug trends.
28 January 2026
········
AbbVie stock rises as insurers crater and the Fed week kicks off

AbbVie stock rises as insurers crater and the Fed week kicks off

New York, Jan 27, 2026, 14:28 EST — Regular session AbbVie Inc. shares climbed roughly 1.5% to $224.12 in Tuesday afternoon trading, having peaked earlier at $226.83. Johnson & Johnson also rose about 1.5%, and Pfizer was up around 2.6%. Meanwhile, Eli Lilly fell close to 1.2%. The move is crucial as the market attempts to sustain a rally ahead of a packed week of earnings and a new Federal Reserve meeting. In healthcare, money is flowing quickly — drugmakers have shown more stability compared to insurers, who are facing pressure from policy uncertainty. The S&P 500 hit a new
27 January 2026
·····
AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings

AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings

New York, Jan 26, 2026, 20:53 EST — Market closed. AbbVie Inc. shares ended Monday 0.7% higher, closing at $220.77, after fluctuating between $218.84 and $221.48 during the session. (Investing.com) The stock rise happened alongside a stronger Wall Street, with investors gearing up for the Federal Reserve’s policy announcement on Wednesday and earnings reports from major tech giants. “Communications and technology are outperforming … in anticipation of earnings from many of the big players,” said Chris Zaccarelli, chief investment officer at Northlight Asset Management. (Reuters) AbbVie’s next key date is Feb. 4, when it will release its full-year and Q4
27 January 2026
·····
AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

New York, January 26, 2026, 14:50 (EST) — Regular session AbbVie Inc. shares edged up roughly 0.4% to hit $220.10 in afternoon trading on Monday, fluctuating between $217.15 and $221.48 earlier in the session. The stock’s modest shift is notable since it hits a key pressure point for the sector: earnings, guidance, and Washington risk are all converging now. Health-care stocks have attracted buyers following a late-2025 rally, despite analysts lowering their fourth-quarter earnings growth outlook to roughly 0.2% year over year, according to Charles Schwab. The note highlighted FactSet projections for AbbVie, expecting earnings per share of $2.65 on
26 January 2026
·····
1 2 3 … 7

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop